EX-5.1 2 d492423dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO    787 Seventh Avenue            
   New York, NY 10019-6099
   Tel: 212 728 8000                
   Fax: 212 728 8111               

January 9, 2018

Melinta Therapeutics, Inc.

300 George Street

Suite 301

New Haven, Connecticut 06511

 

  Re:    Melinta Therapeutics, Inc. Registration Statement on Form S-3

Ladies and Gentlemen:

We have acted as counsel to Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), of a registration statement on Form S-3 (the “Registration Statement”) relating to the sale from time to time, pursuant to Rule 415 of the General Rules and Regulations promulgated under the Securities Act by the selling stockholders named in the Registration Statement (the “Selling Stockholders”) of up to 9,392,198 shares of common stock, par value $0.001 per share, of the Company (the “Shares”), which includes (i) 6,729,459 Shares issued to Vatera Healthcare Partners LLC (“Vatera”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 8, 2017, as amended, by and among the Company, Cempra, Inc. and Castle Acquisition Corp., (ii) 2,000,000 Shares issued to Vatera (222,222 of which were assigned to its affiliate VHPM Holdings LLC) pursuant to that certain Commitment Letter, dated as of November 28, 2017 (the “Vatera Commitment Letter”), between the Company and Vatera, and (iii) 662,739 Shares issued by the Company to JWC Rib-X LLC, Falcon Flight, LLC, and M Participations Ltd., as assignees of Vatera, pursuant to the exercise of the Purchase Option (as defined in the Registration Statement) under the Vatera Commitment Letter.

We have examined, among other things, originals and/or copies (certified or otherwise identified to our satisfaction) of such documents, papers, statutes, and authorities as we have deemed necessary to form a basis for the opinion hereinafter expressed. In our examination, we have assumed the genuineness of all signatures and the conformity to original documents of all copies submitted to us. As to various questions of fact material to our opinion, we have relied on statements and certificates of officers and representatives of the Company.

NEW YORK    WASHINGTON    HOUSTON    PARIS    LONDON    FRANKFURT     BRUSSELS    MILAN    ROME

in alliance with Dickson Minto W.S., London and Edinburgh


Melinta Therapeutics, Inc.

January 9, 2018

Page 2

We have also assumed that:

 

  (i) the Registration Statement will be effective and will comply with all applicable laws at the time the Shares are offered, as contemplated by the Registration Statement; and

 

  (ii) all Shares will be sold in compliance with applicable federal and state securities laws and in the manner stated in the Registration Statement and any prospectus supplement relating thereto.

Based upon and subject to the foregoing, and subject to the limitations, qualifications, exceptions and assumptions expressed herein, we are of the opinion that, with respect to the Shares to be offered pursuant to the Registration Statement by the Selling Stockholders, such shares have been duly authorized and are validly issued, fully paid and non-assessable.

This opinion is limited to the General Corporation Law of the State of Delaware, and we express no opinion with respect to the laws of any other jurisdiction or any other laws of the State of Delaware.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption “Legal Matters” in the prospectus contained in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act.

This opinion letter is rendered as of the date first written above and we disclaim any obligation to advise you of facts, circumstances, events or developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Selling Stockholders or the Shares.

Very truly yours,

 

/s/ Willkie Farr & Gallagher LLP

 

- 2 -